Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis

Archives of Neurology

Volumn 66, Issue 1, 2009, Pages 54-59

  Gorman, Mark P ^a,b   Healy, Brian C ^a   Polgar Turcsanyi, Mariann ^a   Chitnis, Tanuja ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA1A INTERFERON; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; MONOCLONAL ANTIBODY; STEROID;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; ETHNICITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; PRIORITY JOURNAL; RECURRENT DISEASE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE FACTORS; AGE OF ONSET; AGING; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPORTIONAL HAZARDS MODELS; RECURRENCE;

EID: 58449087670     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2008.505     Document Type: Article

References (38)

1. Duquette P, Murray TJ, Pleines J, et al. Multiple sclerosis in childhood: clinical profile in 125 patients. J Pediatr. 1987;111(3):359-363.
2. Simone IL, Carrara D, Tortorella C, et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology. 2002;59(12):1922-1928.
3. Renoux C, Vukusic S, Mikaeloff Y, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007;356(25):2603-2613.
4. Trojano M, Paolicelli D, Bellacosa A, Fuiani A, Cataldi S, Di Monte E. Atypical forms of multiple sclerosis or different phases of a same disease? Neurol Sci. 2004;25(suppl 4):S323-S325.
5. Gauthier SA, Glanz BI, Mandel M, Weiner HL. A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study. Autoimmun Rev. 2006;5(8):532-536.
6. Krupp LB, Banwell B, Tenembaum S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology. 2007;68(16)(suppl 2):S7-S12.
7. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-127.
8. Lawless JF, Nadeau JC. Some simple robust methods for the analysis of recurrent events. Technometrics. 1995;37(2):158-168.
9. Lin DY, Wei LJ, Yang I, Ying Z. Semiparametric regression for the mean and rate functions of recurrent events. J R Stat Soc Ser B Stat Methodol. 2000;62(4):711-730.
10. Cook RJ, Lawless JF. Analysis of repeated events. Stat Methods Med Res. 2002;11(2):141-166.
11. Venables WN, Ripley BD. Modern Applied Statistics With S-PLUS. New York, NY: Springer; 1999.
12. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain. 1980;103(2):281-300.
13. Panelius M. Studies on epidemiological, clinical and etiological aspects of multiple sclerosis. Acta Neurol Scand. 1969(suppl 39):31-82.
14. Leibowitz U, Alter M, Halpern L. Clinical studies of multiple sclerosis in Israel, 3: clinical course and prognosis related to age at onset. Neurology. 1964;14:926-932.
15. McAlpine D, Compston N. Some aspects of the natural history of disseminated sclerosis. Q J Med. 1952;21(82):135-167.
16. Broman T, Andersen O, Bergmann L. Clinical studies on multiple sclerosis, I: presentation of an incidence material from Gothenburg. Acta Neurol Scand. 1981;63(1):6-33.
17. Held U, Heigenhauser L, Shang C, Kappos L, Polman C. Predictors of relapse rate in MS clinical trials. Neurology. 2005;65(11):1769-1773.
18. Sormani MP, Rovaris M, Comi G, Filippi M. A composite score to predict short-term disease activity in patients with relapsing-remitting MS. Neurology. 2007;69(12):1230-1235.
19. Fog T, Linnemann F. The course of multiple sclerosis in 73 cases with computer-designed curves. Acta Neurol Scand Suppl. 1970;47:3-175.
20. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study, 2: predictive value of the early clinical course. Brain. 1989;112(Pt 6):1419-1428.
21. Kennedy J, O'Connor P, Sadovnick AD, Perara M, Yee I, Banwell B. Age at onset of multiple sclerosis may be influenced by place of residence during childhood rather than ancestry. Neuroepidemiology. 2006;26(3):162-167.
22. Ness J, Middleton S, Harris Y, et al. Increased African-American Representation in a Pediatric Multiple Sclerosis Cohort. Paper presented at: 36th Annual Meeting of the Child Neurology Society; 2007; Quebec City, QC.
23. Cree BA, Khan O, Bourdette D, et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology. 2004;63(11):2039-2045.
24. Ghezzi A. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study. Neurol Sci. 2005;26(suppl 4):S183-S186.
25. Pohl D, Rostasy K, Gartner J, Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology. 2005;64(5):888-890.
26. Tenembaum SN, Segura MJ. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology. 2006;67(3):511-513.
27. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group [erratum published in Lancet. 1999;353(9153):678]. Lancet. 1998;352(9139):1498-1504.
28. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):655-661.
29. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285-294.
30. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268-1276.
31. Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffrey DR, Musch B. The REGARD trial: a randomised assessor-blinded trial comparing interferon beta-1a and glatiramer acetate in relapsing-remitting multiple sclerosis. Paper presented at: 23rd Congress of the European Committee for the Treatment and Research in Multiple Sclerosis; 2007; Prague, Czech Republic.
32. Cadavid D, Wolansky L, Cook S, Halper J, Hill J. Betaseron versus Copaxone in multiple sclerosis with triple-dose gadolinium and 3-T MRI endpoints (BECOME): announcement of secondary clinical outcomes. Paper presented at: 23rd Congress of the European Committee for the Treatment and Research in Multiple Sclerosis; 2007; Prague, Czech Republic.
33. Kokmen E, Ozsarfati Y, Beard CM, O'Brien PC, Rocca WA. Impact of referral bias on clinical and epidemiological studies of Alzheimer's disease. J Clin Epidemiol. 1996;49(1):79-83.
34. Lamont EB, Hayreh D, Pickett KE, et al. Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst. 2003;95(18):1370-1375.
35. Lucchinetti CF, Parisi J, Bruck W. The pathology of multiple sclerosis. Neurol Clin. 2005;23(1):77-105, vi.
36. Banwell BL. Pediatric multiple sclerosis. Curr Neurol Neurosci Rep. 2004;4(3):245-252.
37. Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D. Early onset multiple sclerosis: a longitudinal study. Neurology. 2002;59(7):1006- 1010.
38. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343(20):1430- 1438.